The antibody was purified by affinity chromatography and conjugated with PE/Cy7 under optimal conditions. The solution is free of unconjugated PE/Cy7 and unconjugated antibody.
MKI67 antikoerper, kia antikoerper, mki67 antikoerper, MGC132156 antikoerper, D630048A14Rik antikoerper, Ki-67 antikoerper, Ki67 antikoerper, KIA antikoerper, MIB-1 antikoerper, marker of proliferation Ki-67 antikoerper, marker of proliferation Ki-67 L homeolog antikoerper, marker of proliferation Ki-67 S homeolog antikoerper, antigen identified by monoclonal antibody Ki 67 antikoerper, antigen identified by monoclonal antibody Ki-67 antikoerper, nucleolar protein interacting with the FHA domain of MKI67 antikoerper, MKI67 antikoerper, mki67 antikoerper, mki67.L antikoerper, mki67.S antikoerper, Mki67 antikoerper, NIFK antikoerper
Hintergrund
Antigen Ki-67 is a nuclear protein expressed as two isoforms with molecular weights of 395 and 345 kD. Both isoforms contain one forkhead-associated domain and 16 concatenated "Ki-67 repeats," each containing the epitope recognized by the mAb Ki-67. The antigen Ki-67 interacts with Hklp2, hNIFK, and chromobox protein homolog 1, 3, and 5. Ki-67 is required for cell proliferation and its expression is restricted to the phases G1, S, G2, and M of the cell cycle. This characteristic makes Ki-67 an excellent marker for proliferating cells and is commonly used as one of the prognostic factors in cancer studies. Ki-67 has also been used to study myocyte proliferation after myocardial infarction as well as lymphocyte proliferation during infection, and has been used in neurons of patients with different neuropathologies.